Related Experiment Video

Updated: Aug 26, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

microRNA-205 in prostate cancer: Overview to clinical translation

Neeraj Chauhan1, Anjali Manojkumar1, Meena Jaggi1

  • 1Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.

Biochimica Et Biophysica Acta. Reviews on Cancer
|October 3, 2022
PubMed

Insights

MicroRNA-205 (miR-205) acts as a tumor suppressor in prostate cancer (PrCa), regulating key cellular functions. This review highlights miR-205

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer (PrCa) is a leading cancer in US men.
  • Metastatic and advanced PrCa exhibit drug resistance, complicating treatment.
  • MicroRNAs (miRNAs) are crucial in cancer diagnostics, prognostics, and therapeutics.

Purpose of the Study:

  • To review the tumor-suppressive functions of microRNA-205 (miR-205) in prostate cancer.
  • To outline miR-205's role in targeted chemosensitization and radiosensitization.
  • To discuss delivery strategies for clinical translation of miR-205 therapy.

Main Methods:

  • Literature review of studies on miR-205 in prostate cancer.
  • Analysis of miR-205's regulatory roles in cellular processes (proliferation, invasion, apoptosis).
  • Examination of miR-205's potential as a biomarker and therapeutic agent.

Main Results:

  • miR-205 functions as a tumor suppressor in PrCa.
  • miR-205 regulates critical cellular functions including proliferation, invasion, migration, and apoptosis.
  • miR-205 demonstrates potential for diagnostic, prognostic, and therapeutic applications in PrCa.

Conclusions:

  • miR-205 is a key biomarker and therapeutic target in prostate cancer.
  • miR-205 can enhance chemosensitivity and radiosensitivity in PrCa.
  • miR-205 holds promise as an adjuvant therapy to improve clinical outcomes for PrCa patients.
Keywords:
BiomarkerChemosensitizationChemotherapyProstate cancerRadiationmicroRNA

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K